CCM
IBB icon

Consolidated Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Consolidated Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,629
Closed -$1.17M – 45
2018
Q3 		$1.17M Sell
9,629
-123
-1% -$14.5K 0.77% 27
2018
Q2 		$1.07M Buy
9,752
+86
+0.9% +$9.2K 0.8% 27
2018
Q1 		$1.03M Buy
+9,666
New +$1.07M 0.82% 27

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Consolidated Capital Management's IBB Position: Q4 2018 in Review

Consolidated Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2018, closing a stake of 9,629 shares — an estimated $1.17M sold.

Consolidated Capital Management first reported a position in IBB in Q1 2018 and held it in 3 quarters. The position peaked at $1.17M in Q3 2018. 649 funds tracked by Wall St. Rank hold IBB as of Q4 2018.

  • Consolidated Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2018 after selling out during the quarter.
  • Consolidated Capital Management sold 9,629 iShares Biotechnology ETF shares in Q4 2018, an estimated $1.17M.
  • Consolidated Capital Management first reported a position in iShares Biotechnology ETF in Q1 2018 and held it in 3 quarters.
  • Consolidated Capital Management's iShares Biotechnology ETF position peaked at $1.17M in Q3 2018.
  • 649 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2018.

Based on Consolidated Capital Management's 13F filing for Q4 2018, filed 17 Jan 2019.